Fig. 4From: Optimal empiric treatment for KPC-2-producing Klebsiella pneumoniae infections in critically ill patients with normal or decreased renal function using Monte Carlo simulationThe MIC distribution of CMS in monotherapy or combination with FOS against 136 KPC-producing Klebsiella pneumoniae, and probability of target attainment (PTA) of 60 AUC24/MIC for TGC dosing regimens in critically ill elderly patients with normal renal function (Left) and renal impairment (right). The dotted line indicates the PTA of 0.9. FOS, fosfomycin; CST, colistin; CMS, colistin methanesulfonate; MIU, million IUBack to article page